LIGAND PHARMACEUTICALS INC's ticker is LGND and the CUSIP is 53220K504. A total of 363 filers reported holding LIGAND PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is 1.44 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $275,000 | +32.2% | 4,567 | +57.9% | 0.00% | – |
| Q2 2023 | $208,000 | +2.5% | 2,892 | +4.4% | 0.00% | – |
| Q1 2023 | $203,000 | -20.7% | 2,770 | -6.6% | 0.00% | -100.0% |
| Q3 2022 | $256,000 | -3.4% | 2,967 | +0.1% | 0.00% | 0.0% |
| Q2 2022 | $265,000 | -20.4% | 2,964 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $333,000 | -29.0% | 2,964 | -2.5% | 0.00% | 0.0% |
| Q4 2021 | $469,000 | +11.9% | 3,041 | +0.6% | 0.00% | 0.0% |
| Q3 2021 | $419,000 | +6.3% | 3,023 | +0.7% | 0.00% | 0.0% |
| Q2 2021 | $394,000 | -14.0% | 3,003 | -0.3% | 0.00% | 0.0% |
| Q1 2021 | $458,000 | +48.7% | 3,012 | -2.4% | 0.00% | 0.0% |
| Q4 2020 | $308,000 | +6.2% | 3,085 | +1.4% | 0.00% | 0.0% |
| Q3 2020 | $290,000 | -15.5% | 3,043 | -9.7% | 0.00% | -50.0% |
| Q2 2020 | $343,000 | +26.1% | 3,369 | +240.3% | 0.00% | 0.0% |
| Q3 2018 | $272,000 | -55.6% | 990 | -77.9% | 0.00% | -60.0% |
| Q3 2017 | $613,000 | – | 4,474 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| KNOTT DAVID M | 353,041 | $36,819,000 | 14.92% |
| CARDINAL CAPITAL MANAGEMENT LLC /CT | 919,994 | $95,946,000 | 2.93% |
| Elk Creek Partners, LLC | 236,862 | $24,702,000 | 2.84% |
| Conestoga Capital Advisors, LLC | 619,653 | $64,624,000 | 1.56% |
| WOODSTOCK CORP | 71,489 | $7,456,000 | 1.21% |
| Summit Creek Advisors LLC | 70,962 | $7,401,000 | 1.16% |
| FALCON POINT CAPITAL, LLC | 8,115 | $846,000 | 1.08% |
| RICE HALL JAMES & ASSOCIATES, LLC | 302,503 | $31,548,000 | 1.07% |
| Stephens Investment Management Group LLC | 508,100 | $52,990,000 | 1.00% |
| Tygh Capital Management, Inc. | 55,672 | $5,806,000 | 0.96% |